Related Experiment Video
Updated: Mar 3, 2026
02:47
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
2.1K
Pro-resolution therapeutics for cardiovascular diseases.
Justin Heinz1, Michael Marinello1, Gabrielle Fredman1
1Department of Molecular and Cellular Physiology, Albany Medical College, Albany, 12208, NY, USA.
Prostaglandins & Other Lipid Mediators
|April 29, 2017
Summary
Specialized pro-resolving mediators (SPMs) help resolve inflammation and repair tissue. Their imbalance is linked to atherosclerosis, making SPMs a promising therapeutic target for this cardiovascular disease.
Area of Science:
- Biomedical Science
- Cardiovascular Research
- Inflammation Biology
Background:
- Atherosclerosis progression is driven by unresolved chronic inflammation.
- Specialized pro-resolving mediators (SPMs), including lipoxins, resolvins, protectins, and maresins, are key to resolving inflammation and repairing tissue.
- An imbalance between SPMs and pro-inflammatory mediators like leukotriene B4 (LTB4) is implicated in atherosclerosis and other human diseases.
Purpose of the Study:
- To review recent advances in applying SPMs for atherosclerosis treatment.
- To explore the potential of SPMs in managing cardiovascular disease risk factors.
Main Methods:
- Literature review of studies on SPMs and atherosclerosis.
- Analysis of SPM functions in inflammation resolution and tissue repair.
- Examination of the role of SPMs in cardiovascular disease risk factors.
Main Results:
- SPMs are crucial for resolving inflammation and repairing arterial tissue damage in atherosclerosis.
- Imbalances in SPM levels are associated with atherosclerosis development and progression.
- SPMs demonstrate potential in controlling cardiovascular disease risk factors.
Conclusions:
- SPMs represent a significant therapeutic strategy for atherosclerosis due to their anti-inflammatory and tissue-repairing properties.
- Further research into SPMs could lead to novel treatments for cardiovascular diseases.
More Related Videos
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.4K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.4K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
555
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
555
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
599
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
599
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
516
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
516
01:26Atherosclerosis III: Management
529
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
529
01:27Coronary Artery Disease V: Interprofessional Care
347
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
347